Background: Renal dysfunction (RD) is a potent risk factor for death in patients with cardiovascular disease. This relationship may be causal since experimentally induced RD produces findings such as myocardial necrosis and apoptosis in animals. Cardiac transplantation provides an opportunity to investigate this hypothesis in humans; if direct myocardial damage is principally responsible for the substantial risk associated with RD, this risk should be transferable from a donor with RD to the recipient via the allograft.
 Table of 
Introduction:
Renal dysfunction (RD) is common in patients with cardiovascular disease and is strongly associated with increased morbidity and mortality. [1] [2] [3] [4] [5] [6] [7] Notably, this association persists after extensive adjustment for potential confounders, such as diabetes or hypertension, raising the possibility of a causal relationship. One potential mechanism by which RD may directly worsen outcomes is via direct myocardial damage. [8] [9] [10] [11] [12] Support for this possibility is derived from animal studies where experimentally induced RD results in pathology such as necrosis, apoptosis, fibrosis, arteriolar thickening, decreased capillary density, and contractile dysfunction. [13] [14] [15] [16] [17] [18] [19] Remarkably, some of these findings have also been reported following only brief exposures to RD in the setting of experimental acute kidney injury (AKI). 20 Whether RD can cause direct myocardial damage in humans with enough severity to influence outcomes is unknown and represents a difficult hypothesis to test. In addition to potential direct myocardial effects, the epidemiologic signal for adverse outcomes associated with RD could also be driven by non-myocardial/peripheral factors intrinsic to the RD milieu, which are difficult to measure. These factors could take the shape of systemic myocardial depressant factors (i.e., "uremic toxins") effects on the vasculature and other organs, in addition to unmeasured confounding factors (i.e., underutilization of beneficial therapies due to the RD or unmeasured disease severity).
Cardiac transplantation provides an opportunity to begin to investigate the importance of myocardial vs. peripheral effects of RD since the heart is being 2 transplanted into and out of the RD environment. When a heart is removed from a donor with RD, the peripheral RD environment will remain with the donor. However, any RDinduced myocardial damage will travel to the recipient with the graft. Thus, if significant myocardial damage occurs with RD we would expect this injury to travel with the heart and result in reduced post-transplant graft survival in recipients ( Figure 1 ). 21 In essence, this finding would be similar to the concept that the myocardial damage induced by factors such a longer graft ischemic time or from advanced donor age results in worsened post-transplant outcomes (despite the rigorous graft selection process that seeks to avoid these exposures).
Figure 1. Hypothetical effect of donor RD on graft survival in recipients under assumption that donor RD causes direct myocardial damage
Similarly, transplanting a healthy heart into a recipient with RD would be expected to result in a progressive increase in risk over time after enough myocardial damage accumulates from the RD to begin to impact clinical outcomes( Figure 2 ). However, if the risk associated with RD is primarily driven by the host's peripheral RD environment (i.e., systemic myocardial depressant factors), we would expect to see limited risk from donor RD but a significant up-front risk associated with transplant of a healthy donor heart into the environment of recipient RD. That is, we would expect the rate of graft failure to be accelerated post-transplantation in a group of recipients with RD followed by stabilization in the rate of graft failure between the two groups following a critical period of time ( Figure 3 ). Hypothetical effect of recipient RD graft survival in recipients under assumption that RD is a marker of patient disease severity rather then causes direct myocardial damage
Study aim:
As such, the primary purpose of this analysis was to evaluate the risk associated with donor RD on post-transplant outcomes and to determine the temporal pattern of cardiovascular risk associated with recipient RD following transplantation of healthy donor hearts. This was accomplished using heart transplant records from United Network for Organ Sharing (UNOS) database, which is a national database that collects recipient and donor heart transplant data via established questionnaires distributed to all of the transplant centers.
Hypothesis 1:
It is unlikely that renal dysfunction exerts direct damaging effect on myocardium and thus transplantation of donor hearts with and without history of RD will yield similar recipient graft outcomes.
Hypothesis 2:
It is unlikely that renal dysfunction exerts direct damaging effect on myocardium and thus transplantation of donor hearts with and without history of proteinuria will yield similar recipient graft outcomes.
Hypothesis 3:
It is unlikely that renal dysfunction exerts direct damaging effect on myocardium and thus transplantation of donor heart into the recipient environment of RD will not result in a time-dependent acceleration in graft failure compared to donor graft transplantation into recipients with no history of RD. Instead, we would expect to see a significant up-front risk associated with transplant of a healthy donor heart into the environment of recipient RD.
Methods:
Patient Population:
Cardiac transplant donor and recipient data were obtained for adult cardiac transplants between January 2000 and March 2013 (N=28,513) from the United Network for Organ Sharing (UNOS) database. Patients receiving either heart-lung or heart-kidney transplants and those with missing data on donor and recipient serum creatinine, donor race, or graft outcomes were excluded. For patients who underwent re-transplantation (n=1,620), only data on the first transplant was retained. Overall, 23,056 patients met the inclusion criteria ( Figure 4 ).
Figure 4. Consort diagram
Estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. 22 Terminal creatinine was used for donor eGFR calculation; serum creatinine at the time of transplant was used for recipient eGFR calculation. Subsequent recipient renal function was evaluated in a subset of patients with follow-up data available (n = 8,802 23 Several donor or recipient dichotomous characteristics had a high degree of missingness (i.e., recipient cigarette use missing >30%) and there was prognostic information associated with the missing state of these variables. To ensure that the multivariable models captured as much risk as possible, these variables were coded using three levels (i.e., cigarette use yes, no, missing).
Statistical Analysis:
The primary focus of this analysis was (1) 
Coding analysis:
All coding necessary for UNOS database cleaning, donor and recipient eGFR estimation, if Race_don eq 1 and gender_don eq "F" EPIsexMultiplier=166.
if Race_don eq 1 and gender_don eq "M" EPIsexMultiplier=163.
if Race_don eq 0 and gender_don eq "F" EPIsexMultiplier=144.
if Race_don eq 0 and gender_don eq "M" EPIsexMultiplier=141.
EXECUTE.
Compute EPIexponent=$sysmis.
if gender_don eq "F" and creat_don LE 0.7 EPIexponent=-0.329.
if gender_don eq "F" and creat_don gt 0.7 EPIexponent=-1.209.
if gender_don eq "M" and creat_don LE 0.9 EPIexponent=-0.411.
if gender_don eq "M" and Creat_don gt 0.9 EPIexponent=-1.209.
compute Episex=$sysmis.
if gender_don="F" Episex= 0.7.
if gender_don="M" Episex=0.9.
EXECUTE.
compute CKD_EPI_donor=$sysmis.
compute CKD_EPI_donor= EPIsexMultiplier*((creat_don/EPIsex)**EPIexponent)*(0.993**age_don).
Coding for stratifying donor and recipient groups into stages:
COMPUTE CKD_EPI_donorstage=$sysmis. Results:
Donor Characteristics:
In total, 23,056 patients met the inclusion criteria. Baseline donor characteristics stratified by presence of donor RD are presented in Table 1 . diabetes, cigarette use, and longer ischemic time were all significantly associated with recipient graft failure ( Figure 5 and Table 2 ). However, there was no significant relationship between donor RD and graft failure (HR=1.05 95% CI 0.98-1.12 p=0.14). Following adjustment for age, the hazard ratio further approached unity (HR= 1.00, 95% CI 0.94-1.07, p=0.92). A similar lack of association between donor RD and graft failure was observed with larger reductions in eGFR and using creatinine-based cut points to define RD ( Figure 5 ). Further adjustment for other donor characteristics (HR=0.99, 95% CI 0.92-1.06, p=0.76) or donor and recipient characteristics did not alter the lack of relationship between donor RD and graft survival (HR= 0.98, 95% CI 0.92-1.05, p=0.60, Table 3 ). A "dose-response" relationship between donor eGFR and graft failure was not apparent as progressively worse donor CKD stages ( Figure 6 ) and eGFR as a continuous parameter (adjusted HR=1.00 per 10 ml/min/1.73m 2 , 95% CI 1.00-1.01, p=0.37) were not associated with increased risk of graft failure. 
Donor proteinuria and graft failure:
In total, 32.6% of donors (n=7,406) had proteinuria at the time of evaluation. Not surprisingly, proteinuria was more common in donors with hypertension (37.1% vs.
31.9%, p<0.001) and in donors with diabetes (41.2% vs. 32.3%, p<0.001). Donor proteinuria was not associated with decreased graft survival (HR=1.00, 95% CI 0.95-1.05, p=0.96, Figure 5 ), and this lack of association persisted with extensive adjustment for donor and recipient characteristics (HR=1.00, 95% CI 0.94-1.06, p=0.97, Figure 7 ). 
Recipient characteristics:
Baseline characteristics of recipients with and without RD are presented in Table   4 . TPG, mm/Hg 9.6 ± 5.4 9.5 ± 5. The mean eGFR of the population was 69.9 ± 26.5 ml/min/1.73m 2 and RD was present in 39.4% of recipients. Amongst recipients with RD, the mean eGFR was 44.7 ± 10.9 ml/min/1.73m
2 . Similar to donors, recipients with RD were older and more likely to have evidence of CVD in the form of ischemic cardiomyopathy and peripheral vascular disease. Additionally, recipients with RD exhibited several indices of increased HF-disease severity including greater utilization of inotropes and intra-aortic balloon pumps and higher filling pressures. Pre-transplant allograft function was similar between recipients with and without RD. When only those recipients who received allografts from RD-free donors were examined (n=18,919), the observed similarities and differences between those recipients with and without RD were similar (data not shown).
Recipient RD and timing of graft failure:
Over the entire follow-up period, recipient RD was significantly associated with poor graft outcomes even following extensive adjustment for donor and recipient The attenuation in risk did not appear to be primarily driven by recovery in renal function; when patients with data on repeat renal function were evaluated (data available 37%, median time to follow-up creatinine = 6.0 years), eGFR in patients with RD did not meaningfully improve post-transplant (baseline eGFR 45.0 ± 10.5 ml/min/1.73m 2 vs.
follow-up eGFR 47.3 ± 20.1 ml/min/1.73m 2 ). Similar findings of an early period of high risk followed by attenuation in risk was observed when examining only cardiac allografts from donors without RD (p interaction = 0.13).
Discussion:

Principal Findings of the Study:
The principal findings of this study are 1) RD in a cardiac donor, regardless of its severity, is not associated with worsened graft survival and 2) the risk of graft failure associated with recipient RD is substantial and most pronounced in the first 30 days following cardiac transplantation with subsequent attenuation in the risk over time. Thus RD-associated risk cannot be transferred between patients via the myocardium, but placement of a healthy myocardium into a host with RD results in immediate worsening in outcomes. The pattern of this risk is most consistent with the concept that the primary source of risk associated with RD is derived from the peripheral or non-myocardial aspects of the cardio-renal environment.
A large body of evidence from animal models has clearly demonstrated that significant adverse myocardial structural changes such as apoptosis, necrosis, and fibrosis occur with experimentally induced RD. [13] [14] [15] [16] [17] [18] [19] [20] Given that these are known mediators of disease in humans, it is reasonable to believe if the above pathology also occurred in humans with RD it would result in worse outcomes. Importantly, despite significant pathologic changes, animal systolic function was only mildly or not impaired at all, suggesting that if this damage occurred in humans it would likely not be avoided during the allograft screening process. 16 Consistent with the above premises, it has previously been reported that factors which plausibly can cause direct myocardial damage such as older donor age, hypertension, and diabetes have been linked to worsened post-transplant graft survival. These findings serve as "positive controls" that subclinical myocardial damage in the donor can be transmitted to the recipient despite the donor screening process. 21, [26] [27] [28] [29] [30] However, even with severe RD in the donor the risk associated with donor RD approached zero in a sample size of >23,000 patients.
Although the graft selection process and complicated peri-transplant management of these patients may have attenuated the signals in this study, the complete lack of a detectable risk with donor RD argues that the peripheral RD environment is the dominant factor in RD-associated risk.
Further support for the above concept is provided by the findings with respect to recipient RD. Importantly, substantial acute systolic dysfunction has not been a predominant finding in animal models of experimentally induced RD and we could not detect any signal for worsened outcomes with donor RD, which was likely acute in the majority of cases. 16 As a result even if myocardial damage began to occur immediately following transplant of a healthy donor heart into a recipient with RD, myocardial dysfunction would not be expected to manifest itself in immediately worsened outcomes.
Rather, only over months to years as myocardial damage accumulated would we expect to see worsened outcomes associated with recipient RD if the myocardial pathology was the dominant driver. To the contrary, we found that when donor hearts were placed into the environment of recipient RD the opposite pattern was apparent with substantially increased risk immediately following transplant, followed by attenuation of the risk over time. Unlike a delayed effect as myocardial injury accumulates from RD, the peripheral aspects of RD such as unmeasured disease severity, underutilization of beneficial therapies (i.e, calcineurin inhibitors), and systemic myocardial depressant factors would be expected to be the most pronounced immediately after transplant. The finding of a substantially increased early risk associated with RD followed by subsequent attenuation is in line with the latter hypothesis.
The direct implication of this study is that transplantation of appropriately selected hearts from donors with even significant RD does not appear to worsen posttransplant outcomes. However, this analysis also may shed some light on potential therapeutic approaches toward cardio-renal dysfunction. If transplantation of a heart from a donor with RD was associated with worse post-transplant outcomes, this would indicate that once cardio-renal syndrome occurs, the damage is likely irreversible.
However, the absence of a risk associated with donor RD and attenuation of the risk associated with recipient RD over time post-transplant suggests that the risk associated with cardio-renal dysfunction may be modifiable. Further research is necessary to better understand the non-myocardial determinants of RD associated risk and evaluate if strategies to improve these risk factors could improve outcomes in these patients.
Study Limitations:
This study is subject to limitations inherent to analyses of a retrospective post-hoc study, such as uncontrolled confounding and reliance on data from a large registry. In conclusion, the risk associated with RD does not appear to be transferrable from donor to recipient via the cardiac allograft and the risk associated with recipient RD is greatest immediately following transplant. Overall these data support the safety of transplantation of appropriately selected allografts from donors with RD. Additionally, these data suggest that the non-myocardial aspects of cardio-renal dysfunction appear to be of particular importance in driving the risk associated with RD. transplantation of a healthy RD-free donor heart into a recipient with RD should yield an initial low risk period followed by high event rates months to years later.
Methods:
Adult cardiac allograft recipients in the UNOS registry were studied (n=35,914). RD was defined as estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m 2 .
Results: RD was present in 17. 
Conclusion:
Transplantation of a heart in and out of the environment of RD was not associated with worsened outcomes in a manner consistent with a clinically meaningful direct effect of RD on the myocardium. These data provide additional support that RD primarily serves as a marker rather than a direct cause of CVD. transplantation of a healthy RD-free donor heart into a recipient with RD should yield an initial low risk period followed by high event rates months to years later.
Methods:
Adult cardiac allograft recipients in the UNOS registry were studied (n=35,914). RD was defined as estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m 2 . 
Results
